Oncolytics Biotech Inc 定于2026年4月16日就Pelareorep用于肛门癌适应症召开FDA C类会议

美股速递
Apr 06

Oncolytics Biotech Inc (ONCY) 已安排于2026年4月16日与美国食品药品监督管理局(FDA)举行C类会议,会议核心议题将聚焦其候选药物Pelareorep在肛门癌领域的应用前景。此次会议旨在就相关研发路径与监管要求进行深入探讨。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10